Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2011 - 2026)

Ani Pharmaceuticals has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting $29.5 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $29.5 million, up 93.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.4 million (up 503.11% YoY), and the FY2025 annual result was $77.2 million, up 483.08% from the prior year.
• Net Income towards Common Stockholders came in at $29.5 million for Q1 2026 at Ani Pharmaceuticals, up from $27.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $29.5 million in Q1 2026 to a low of -$24.6 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is $1.0 million (2023), against an average of $3.2 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 25451.85% in 2022 and surged 1623.23% in 2024, its largest moves.
• Ani Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.6 million in 2022, then soared by 116.11% to $749000.0 in 2023, then tumbled by 1526.17% to -$10.7 million in 2024, then surged by 357.35% to $27.5 million in 2025, then grew by 7.28% to $29.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $29.5 million (Q1 2026), $27.5 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.